SLATE-ASSET-MANAGEMENT
22.7.2022 08:02:07 CEST | Business Wire | Press release
Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced that it has acquired a majority stake in amperio GmbH (“amperio”), a specialist planner and operator of electric vehicle (“EV”) charging infrastructure in Germany.
Amperio is a leading planner and operator of EV charging stations in the highly-fragmented EV charging market in Germany. Since 2012, amperio has been supporting companies, cities, and communities in developing tailored charging concepts, installing charging stations, and providing backend management services for charging stations. To date, amperio has installed over 1,800 intelligent charging points. Amperio maintains, operates, and executes the billing for over 300 of these charging points on behalf of its customers.
As part of the transaction, Slate created Slate Mobility GmbH & Co. KG (“Slate Mobility”), an entity that will finance and own EV charging equipment for Slate and potential third parties and receive management services from amperio. Slate’s portfolio of over 225 grocery properties across Germany and deep network of relationships with tenants focused on environmental sustainability will create a pipeline of opportunities to accelerate amperio’s growth.
Amperio, together with Move About Groups subsidiary mobileeee GmbH (“mobileeee”) and the City of Ludwigshafen in Germany, are implementing a project for station-based public e-carsharing. The project includes the build-up of 27 stations with mobileeee charging infrastructure as well as publicly accessible charging infrastructure. The City Ludwigshafen initiated this concept with the aim of reducing local emissions in the City and its districts.
“To achieve the German government’s target of having at least 15 million electric cars on the roads by 2030 will require significant investment in EV charging points throughout the country,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “Amperio is offering a unique, customizable national product to help meet this demand, backed by a team with a proven track record of experience developing charging infrastructure for cities, communities, and businesses. We are excited to partner with amperio to enhance the sustainability infrastructure of our own properties and improve access to efficient charging points all across Germany.”
“Our partnership with Slate presents an exciting opportunity to scale our business and provide seamless and sustainable mobility solutions that are so urgently needed to protect the climate,” added Oliver P. Kaul, Managing Director of amperio. “Our environment has given us the assignment to create zero-emission mobility. Slate has offered us its properties and the funding to accelerate that mission, which amperio embarked on 10 years ago. Together, we strive to achieve our goal of making clean EV charging technology and services widely available.”
Slate is an active investor in sustainable assets and technologies that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals. Slate’s most recent impact infrastructure investment was a commitment to Eider VF Limited, a UK-based vertical farming business sustainably growing leafy produce to be sold to the UK mass market.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities.
Visit slateam.com to learn more.
About amperio
amperio GmbH is a specialist planner for charging infrastructure based in Cologne. Since 2012, amperio has been supporting companies, cities and municipalities in developing individual charging concepts, installing charging stations and billing charging processes. In doing so, amperio relies on a holistic service that leaves no customer wishes unfulfilled. This includes location analysis, profitability analysis, business model analysis, technical consulting, backend service (monitoring and billing), the operation of charging points, and energy management and subsidy consulting. In addition, amperio offers two charging infrastructure concepts developed in-house with its CHARGE2GO and Mitarbeiter-Strom products. The company has already installed over 1,800 charging points for customers such as Globus, DKB, Groupe PSA, the city of Düren, Volvo, the city of Bad Ems and the MNT Group.
amperio GmbH is part of Slate Asset Management, a global alternative investment platform, which holds a majority stake in amperio GmbH.
Visit amperio.eu to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005973/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
